Search research articles
Contact Us
Filters
Showing results (61-70 of 110) with videos related to
Page
of 11
Sort By:
Hemasphere
|
April 26, 2021
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
Lisa C Holthof, Arwen Stikvoort, Hilma J van der Horst, et al.
Human Immunology
|
February 1, 2003
Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides
Jan H Kessler, Bregje Mommaas, Tuna Mutis, et al.
Mabs
|
March 12, 2015
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B Overdijk, Sandra Verploegen, Marijn Bögels, et al.
Materials Today. Bio
|
March 10, 2025
Lymphoma-on-chip model reveals that lymph node stromal cells promote diffuse large B-cell lymphoma survival and migration
Mohammad Jouybar, Aleksandra M Mikula, Nanouk Zuidmeer, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
January 26, 2019
Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma
Anil K Deshantri, Marcel H Fens, Ruud W J Ruiter, et al.
Blood
|
May 26, 2016
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik, Tineke Casneuf, Inger S Nijhof, et al.
Hemasphere
|
June 16, 2021
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma
Arwen Stikvoort, Jort van der Schans, Subhashis Sarkar, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
May 17, 2017
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent, Maria Themeli, Renée Poels, et al.
Cancer Immunology Research
|
March 21, 2019
T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells
Margot J Pont, Rimke Oostvogels, Cornelis A M van Bergen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 2023
Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138
Jort J van der Schans, Ziyu Wang, Jennemiek van Arkel, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 110) with videos related to
Sort By:
Page
of 11
Hemasphere
|
April 26, 2021
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
Lisa C Holthof, Arwen Stikvoort, Hilma J van der Horst, et al.
Human Immunology
|
February 1, 2003
Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides
Jan H Kessler, Bregje Mommaas, Tuna Mutis, et al.
Mabs
|
March 12, 2015
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B Overdijk, Sandra Verploegen, Marijn Bögels, et al.
Materials Today. Bio
|
March 10, 2025
Lymphoma-on-chip model reveals that lymph node stromal cells promote diffuse large B-cell lymphoma survival and migration
Mohammad Jouybar, Aleksandra M Mikula, Nanouk Zuidmeer, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
January 26, 2019
Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma
Anil K Deshantri, Marcel H Fens, Ruud W J Ruiter, et al.
Blood
|
May 26, 2016
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik, Tineke Casneuf, Inger S Nijhof, et al.
Hemasphere
|
June 16, 2021
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma
Arwen Stikvoort, Jort van der Schans, Subhashis Sarkar, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
May 17, 2017
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent, Maria Themeli, Renée Poels, et al.
Cancer Immunology Research
|
March 21, 2019
T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells
Margot J Pont, Rimke Oostvogels, Cornelis A M van Bergen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 2023
Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138
Jort J van der Schans, Ziyu Wang, Jennemiek van Arkel, et al.
Page
of 11